Verve Therapeutics Inc. (VERV)
4.59
0.08 (1.77%)
At close: Apr 17, 2025, 3:59 PM
4.64
1.09%
After-hours: Apr 17, 2025, 07:59 PM EDT
1.77% (1D)
| Bid | 4.56 |
| Market Cap | 407.57M |
| Revenue (ttm) | 32.33M |
| Net Income (ttm) | -198.71M |
| EPS (ttm) | -2.35 |
| PE Ratio (ttm) | -1.95 |
| Forward PE | -1.71 |
| Analyst | Strong Buy |
| Ask | 4.64 |
| Volume | 2,586,491 |
| Avg. Volume (20D) | 2,590,401 |
| Open | 4.56 |
| Previous Close | 4.51 |
| Day's Range | 4.42 - 4.84 |
| 52-Week Range | 2.87 - 9.30 |
| Beta | 1.87 |
About VERV
Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program to permanently turn off the ANGPTL3 gene in the liver. It has a collaboration and license agreement with...
Industry Biotechnology
Sector Healthcare
IPO Date Jun 17, 2021
Employees 274
Stock Exchange NASDAQ
Ticker Symbol VERV
Website https://www.vervetx.com
Analyst Forecast
According to 5 analyst ratings, the average rating for VERV stock is "Strong Buy." The 12-month stock price forecast is $24, which is an increase of 422.88% from the latest price.
Stock ForecastsNext Earnings Release
Verve Therapeutics Inc. is scheduled to release its earnings on May 7, 2025,
before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription
Analysts project revenue of ... Unlock content with Pro Subscription
5 days ago
+20.63%
Verve Therapeutics shares are trading higher after...
Unlock content with
Pro Subscription
6 days ago
+26.38%
Verve Therapeutics shares are trading higher after the company announced a 69% LDL-C reduction with VERVE-102 in its Heart-2 trial.
